Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$7.06 ▼ -0.38
(-5.11%)
MKT CAP: $205.4M • VOL: 108.9K
52W L $4 52W H $10
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$6
MEDIAN
$8
MEAN
$8
HIGH
$10
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE DTIL TAPE
DTIL // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $8.54 | $8.12 | 2025-02-14 | $6.42 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $8.90 | $8.33 | 2025-02-06 | $6.64 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $8.05 | $7.77 | 2025-01-29 | $6.78 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $7.20 | — | 2025-01-17 | $6.92 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $6.21 | $6.71 | 2025-01-09 | $6.28 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $8.40 | $7.34 | 2024-12-18 | $6.14 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $6.85 | $7.13 | 2024-12-04 | $6.57 | -4.3% | 48% | C |